RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia)

Structure/Sequence

Sequence Code 13363H

Source: *****

Sequence Code 13368L

Source: *****

Clinical Trials associated with Satralizumab

NCT07010302

/ Not yet recruitingPhase 4IIT

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD relapses: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab.
In this study, 160 adults with NMOSD who test positive for a specific antibody (AQP4-IgG) will participate. They will be randomly assigned to receive either rituximab or one of the four other FDA-approved medications. The main goal is to find out which treatment best prevents relapses and has fewer serious side effects. The trial will also measure disability, patient satisfaction, quality of life, and biomarkers that help track disease activity.
Participants will have regular assessments, including medical exams, surveys, and tests for vision, walking ability, and brain function. They will report any side effects or health issues experienced during the study. The trial will last from one to four years for each participant.
This research aims to help patients and doctors make better-informed treatment decisions by providing clear evidence about the best available therapies for NMOSD.

Start Date01 Aug 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07762872

/ RecruitingNot ApplicableIIT

Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Cohort Study

This study is a multicenter, prospective cohort study designed to enroll 50 NMOSD patients who receive Satralizumab treatment during the early phase of an NMOSD attack. Follow-up visits will be conducted at baseline, 3 months, and 6 months to record and assess EDSS scores, modified Rankin Scale (mRS) scores, EQ-5D scores, Activities of Daily Living (ADL) scores, relapse events, safety data, and exploratory endpoints (e.g., blood inflammatory markers and visual function), with the aim of evaluating the efficacy and safety of Satralizumab in the early treatment of NMOSD-thereby providing patients with more effective therapeutic options and further optimizing the clinical management of NMOSD.

Start Date20 Jul 2026

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

[+3]

NCT05199688

/ RecruitingPhase 3

A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.

Start Date06 May 2026

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with Satralizumab

100 Translational Medicine associated with Satralizumab

100 Patents (Medical) associated with Satralizumab

210

Literatures (Medical) associated with Satralizumab

01 Oct 2026·JOURNAL OF NEUROIMMUNOLOGY

Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review

Article

Author: Hasegawa, Tomoya ; Tsuda, Hiroyuki ; Sekikawa, Hiroshi ; Watanabe, Hazuki ; Ando, Takashi ; Goto, Yoji

Neuromyelitis optica spectrum disorder (NMOSD) predominantly affects women of reproductive age, posing significant risks for pregnancy-associated relapses and adverse perinatal outcomes. While biologic agents such as satralizumab are established therapies for NMOSD, data regarding their safety and efficacy when initiated during pregnancy remain scarce. Here we report the case of a 32-year-old woman with a history of NMOSD (diagnosed at age 24), taking oral low-dose prednisolone before conception. To mitigate the risk of relapse, satralizumab was first injected at 28 + 3 weeks of gestation. She delivered vaginally at 40 + 1 weeks of gestation without peripartum complications or disease relapse. Notably, while transplacental transfer of satralizumab was demonstrated, the drug was undetectable in breast milk and the neonate developed normally. To our knowledge, this is the first reported case of satralizumab initiation during pregnancy for relapse prevention in a patient with NMOSD. Our findings suggest that satralizumab may represent a viable therapeutic option for NMOSD management even when pregnancy is already established.

01 Sep 2026·Multiple Sclerosis and Related Disorders

Bridging to low-dose corticosteroids after satralizumab discontinuation in unplanned pregnancy: Two cases of AQP4-positive NMOSD

Letter

Author: Zhang, Wangteng ; Yao, Haiyan ; Li, Shichun ; Shen, Yaokai ; He, Shiyu ; Zhang, Shifeng ; Long, Youming ; Lin, Peihao ; Huang, Li ; Lin, Guanyan ; Li, Ting ; Lai, Wendong

BACKGROUND:

Satralizumab is effective for relapse prevention in AQP4-positive neuromyelitis optica spectrum disorder (NMOSD), but its safety during pregnancy has not been established. While several cases have reported continued satralizumab use in planned pregnancies, the management of unplanned pregnancy in patients already on satralizumab remains undefined.

CASES:

We report two AQP4-positive NMOSD patients (aged 32 and 21 years) who conceived unexpectedly during satralizumab maintenance therapy (8 and 7 months of treatment, respectively). Upon pregnancy confirmation, satralizumab was discontinued. Both patients received low-dose corticosteroid monotherapy throughout gestation as bridging maintenance: one with methylprednisolone 4 mg/day, the other with prednisolone 10 mg/day. No NMOSD relapses occurred during pregnancy. Both delivered healthy full-term neonates without congenital anomalies. Satralizumab was resumed immediately postpartum, with no relapses during follow-up.

CONCLUSION:

Among two AQP4-IgG-positive NMOSD patients with sustained pre-conception remission who experienced unplanned pregnancy during satralizumab maintenance, switching to low-dose corticosteroid monotherapy after drug cessation coincided with relapse-free gestation. The strategy avoids fetal exposure to satralizumab with unconfirmed gestational safety, yet the benign clinical course cannot be solely attributed to steroid bridging. Persistent residual satralizumab activity, inherent long-term disease quiescence, and pregnancy-mediated immune shifts all likely contributed to the stable disease state. These paired clinical observations only generate preliminary hypotheses and cannot support broad clinical recommendations for pregnant NMOSD patients.

01 Aug 2026·JOURNAL OF NEUROIMMUNOLOGY

Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis

Review

Author: Daromar, Adam ; Canibano, Beatriz ; Abushalbak, Dareen Jamal ; AlHabil, Yazan ; Safan, Abeer ; Abualrob, Majd A ; Hamid, Shahd ; Zammar, Khaled

BACKGROUND AND OBJECTIVES:

Monoclonal antibodies have transformed the treatment of neuromyelitis optica spectrum disorder (NMOSD), yet their comparative efficacy by aquaporin-4 immunoglobulin G (AQP4-IgG) serostatus remains uncertain. We conducted a systematic review and meta-analysis to compare monoclonal antibody efficacy between AQP4-IgG seropositive and seronegative NMOSD patients.

METHODS:

We searched PubMed/MEDLINE, Embase, and Cochrane CENTRAL from inception through January 2025 for studies comparing monoclonal antibody efficacy outcomes (rituximab, eculizumab, satralizumab, inebilizumab, tocilizumab, or ravulizumab) between seropositive and seronegative NMOSD patients. Primary outcomes included annualized relapse rate (ARR) and relapse events. Secondary outcomes included disability progression (Expanded Disability Status Scale [EDSS]) and infectious adverse events. Random-effects meta-analysis was performed. The protocol was registered in PROSPERO (CRD1049290).

RESULTS:

Thirteen studies (4 randomized controlled trials [RCTs], 9 observational) comprising 1284 patients (1010 seropositive; 274 seronegative) were included. Seropositive patients had significantly lower relapse risk (risk ratio [RR] = 0.66; 95% CI: 0.49-0.89; p = 0.007; I² = 0%; 9 studies), indicating 34% greater efficacy in preventing relapses. An RCT-only subgroup analysis demonstrated a 59% relative risk reduction favoring seropositive patients (RR = 0.41; 95% CI: 0.25-0.69; p = 0.0008; I² = 0%). No significant differences were observed for continuous ARR (standardized mean difference [SMD] = 0.23; p = 0.61; I² = 94%), disability progression (SMD = 1.07; p = 0.32; I² = 96%), or infectious adverse events (RR = 1.13; p = 0.61; I² = 0%).

DISCUSSION:

Monoclonal antibodies demonstrate significantly greater efficacy in preventing relapses in AQP4-IgG seropositive compared with seronegative NMOSD patients. Serostatus should inform treatment selection and expectations. Comparable safety profiles support continued use in seronegative patients, though further research is needed to optimize therapeutic strategies for this population.

News (Medical) associated with Satralizumab

21 Aug 2026

·www.pharmaceutical-technology.com

Roche commits $750m to double Oregon-based US manufacturing capacity

The new Hillsboro facility will double Roche’s presence in the city, while creating 250 manufacturing jobs. Credit: Photo Spirit / Shutterstock.com. Roche-owned Genentech has tapped the Northwestern state of Oregon as home to a new, $750m injectable manufacturing facility – expanding its presence in the city of Hillsboro and further bolstering its presence on American soil. The Swiss pharma giant plans to build the end-to-end fill-finish production site on the same campus as its current Hillsboro manufacturing facility, and it will will primarily produce a range of portfolio and pipeline injectables from both Roche and its subsidiary, Genentech. To account for changing manufacturing demand, Roche has also put together a flexible blueprint for the site, meaning it will be able to fill both low and high-volume autoinjectors and pre-filled syringes. The company puts these plans in place as the industry’s focus increasingly shifts towards convenient dosing formats suitable for at-home use. While Roche has not disclosed which specific medicines it will produce at its new site, the company currently offers a range of drugs in its portfolio arsenal that are delivered via pre-filled syringe. This includes rare autoimmune disease therapy, Enspryng (satralizumab), as well as anaemia-tackling medications like Neorecormon (epoetin beta) and Mircera (methoxy polyethylene glycol epoetin beta). During the Hillsboro build, Roche expects to hire around 200 construction workers, who will work on the site until its expected completion in 2031. Once the facility is operational, it will house around 250 skilled manufacturing specialists. Big pharma’s US onshoring push Once operational, Roche’s new Hillsboro facility will further expand the company’s presence in the US, which includes 13 manufacturing sites situated across several states. The Oregon site, however, is not the only ongoing production footprint expansion project Roche has in the works. Recently, the Swiss pharma giant completed the structural framework for its $2bn Holly Springs, North Carolina biomanufacturing site, which will produce therapies for metabolic conditions as Roche eyes a slice of the rapidly growing obesity market. Roche’s efforts to boost its manufacturing presence run parallel to a wider trend within big pharma, as companies outlay billions of dollars to build production sites in the US. This shift follows mounting pressure from the Trump administration to onshore drug manufacturing in exchange for tariff reprieve. Previously, experts told Pharmaceutical Technology that the onshoring revolution is giving rise to new biotech hubs around the country, with locations like North Carolina, Virginia and Texas grabbing the attention of pharma for their affordability, strong workforce and favourable tax environments for businesses.

31 Jul 2026

·www.chugai-pharm.co.jp

Chugai Files for Additional Indication of Enspryng as Japan’s Potential First Treatment for Prevention of Relapse in MOG Antibody-associated Disease

A regulatory application for an additional indication of Enspryng for “prevention of relapse in MOG antibody-associated disease” was filed in Japan Enspryng received forerunner designation in 2023 as a treatment for the disease If approved, Enspryng would become the first treatment covered by health insurance in Japan for the disease TOKYO, July 31, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) today for an additional indication of “prevention of relapse in MOG antibody-associated disease” for Enspryng® [generic name: satralizumab (genetical recombination)], a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. “MOG antibody-associated disease (MOGAD) is a rare autoimmune disease in which repeated relapses may leave neurological symptoms, such as visual field and vision impairment, as well as paralysis, causing long-term impacts on patients’ lives. In a global Phase III study, Enspryng reduced the risk of relapse by 68% compared with placebo. We will work closely with the regulatory authority so that we can deliver Enspryng to patients with this disease, for which there are currently no approved treatments, as soon as possible,” said Chugai’s President and CEO, Dr. Osamu Okuda. This filing is based on results from METEOROID, a global phase III clinical study in adults and adolescents (aged 12-17 years) with MOGAD. Development in Japan is conducted by Chugai, and Japanese patients have participated in this study. [Reference] Roche’s Announcement Regarding New Data of Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) (Apr. 22, 2026 news release) https://www.chugai-pharm.co.jp/english/news/detail/20260422153000_1246.html Chugai Receives Forerunner Designation for Enspryng in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) and Autoimmune Encephalitis (AIE) (Mar. 24, 2023 news release) https://www.chugai-pharm.co.jp/english/news/detail/20230324150001_976.html About Enspryng Enspryng, created by Chugai, is a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody, which was the first product developed by applying Chugai’s proprietary recycling antibody® technology. Recycling antibody technology received “The Imperial Invention Prize,” the highest honor of the FY2026 National Commendation for Invention.1 Enspryng is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in approximately 90 countries, including Japan, the United States, and Europe. A global phase III clinical study is currently ongoing in autoimmune encephalitis (AIE). In addition, the U.S. Food and Drug Administration (FDA) has accepted the filing for thyroid eye disease (TED) and granted priority review. About MOG antibody-associated disease (myelin oligodendrocyte glycoprotein antibody-associated disease, MOGAD) MOGAD is an autoimmune disease involving demyelination by which a pathogenic autoantibody, an anti-MOG antibody, binds to MOG, which is expressed on the surface of the myelin sheath in the central nervous system. MOGAD causes inflammation of the optic nerves, spinal cord and brain, with symptoms such as visual impairment, loss of sensation, motor dysfunction and dysuria.2,3 Currently, no approved therapies exist for the prevention of relapse in MOGAD, and in about 80% of adult patients, the disease is chronic and characterized by a relapsing course with currently used therapies. Therefore, high unmet medical needs remain.2-8 The inflammatory cytokine IL-6 may play a role in the pathogenesis of MOGAD by promoting the production of autoantibodies9 and inducing inflammatory effects.10 The number of patients in Japan is estimated to be approximately 1,700.11 Trademarks used or mentioned in this release are protected by law. Sources:

Phase 3Priority ReviewClinical ResultDrug Approval

24 Jul 2026

·www.chugai-pharm.co.jp

Chugai Announces 2026 2nd Quarter Results

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc. Jul 24, 2026 Corporate TOKYO, July 24, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the second quarter of fiscal year 2026. Core revenue of ¥663.3 billion (+14.7%), core operating profit of ¥329.1 billion (+21.0%), and core net income of ¥238.4 billion (+23.2%) were achieved (all changes year-on-year) Strong growth in domestic and overseas sales, combined with a significant increase in other revenue driven by one-time income, and royalty income related to Hemlibra® and NEMLUVIO®, resulted in increased revenue and profit year-on-year Achieved eight regulatory filings in Japan during the first half of the year, progressing steadily toward achieving the highest number of filings ever planned R&D activities progressed steadily across both early- and late-stage development, including Chugai-originated projects For NXT007, which is expected to become a next-generation growth driver, two Phase III studies were initiated For AQUA07, the third macrocyclic peptide project, entry into the clinical stage was achieved, with dosing in a Phase I study in ALK-positive non-small cell lung cancer expected to start shortly For Enspryng®, developed using Chugai’s proprietary antibody engineering technologies, the U.S. FDA accepted the regulatory application for thyroid eye disease (TED) and granted Priority Review designation Regarding products out-licensed to third parties, global market penetration of Chugai-originated new products advanced Export sales and royalty income from NEMLUVIO (nemolizumab), a humanized anti-human IL-31 receptor A monoclonal antibody out-licensed to Galderma, drove revenue growth As for Foundayo™ (orforglipron), an oral GLP-1 receptor agonist out-licensed to Eli Lilly, prescriptions were driven in the U.S. primarily by GLP-1 naïve patients, and the oral anti-obesity drug market is expanding. Chugai commenced recognition of royalty income from the product in the second quarter For NXT007, which is expected to become a next-generation growth driver, two Phase III studies were initiated For AQUA07, the third macrocyclic peptide project, entry into the clinical stage was achieved, with dosing in a Phase I study in ALK-positive non-small cell lung cancer expected to start shortly For Enspryng®, developed using Chugai’s proprietary antibody engineering technologies, the U.S. FDA accepted the regulatory application for thyroid eye disease (TED) and granted Priority Review designation Export sales and royalty income from NEMLUVIO (nemolizumab), a humanized anti-human IL-31 receptor A monoclonal antibody out-licensed to Galderma, drove revenue growth As for Foundayo™ (orforglipron), an oral GLP-1 receptor agonist out-licensed to Eli Lilly, prescriptions were driven in the U.S. primarily by GLP-1 naïve patients, and the oral anti-obesity drug market is expanding. Chugai commenced recognition of royalty income from the product in the second quarter Refer to the information below for details on the financial results: Quarterly Reports / Finance Reports https://www.chugai-pharm.co.jp/english/ir/reports_downloads/tanshin.html Presentation Materials In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and transcripts (including Q&A) will be made available at a later date. https://www.chugai-pharm.co.jp/english/media/conference.html [2026 Second Quarter Results] 2026 Jan-Jun 2025 Jan-Jun Revenue 663.3 [PDF 142KB] Contact: For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Naoki Kouzai Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Takayuki Sakurai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp Back

Phase 1Phase 3Financial StatementClinical ResultPriority Review

100 Deals associated with Satralizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D11079	Satralizumab	L01XC	DB15762

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
AQP4-IgG positive Neuromyelitis optica spectrum disorder	Australia	Roche Holding AG	17 Nov 2020
Neuromyelitis Optica	Canada	Hoffmann-La Roche Ltd.	01 Jun 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graves Ophthalmopathy	NDA/BLA	United States	Roche Holding AG	30 Jun 2026
Autoimmune Encephalitis	Phase 3	United States	F. Hoffmann-La Roche Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	United States	Roche China Holding Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	China	Roche China Holding Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	China	F. Hoffmann-La Roche Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	Japan	F. Hoffmann-La Roche Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	Japan	Roche China Holding Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	Argentina	F. Hoffmann-La Roche Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	Argentina	Roche China Holding Ltd.	24 Apr 2023
Autoimmune Encephalitis	Phase 3	Australia	F. Hoffmann-La Roche Ltd.	24 Apr 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06106828 (SatraGO-2, CTgov)	Phase 3	Graves Ophthalmopathy	127	Satralizumab (Part I: Satralizumab)	nuxtslabvo = zoghdxkwep ewpypmzirr (uiwfihbwmb, bzazijnfju - yaldrufrnl) View more	-	12 Aug 2026
				placebo+satralizumab (Part I: Placebo)	nuxtslabvo = lybbyythfw ewpypmzirr (uiwfihbwmb, snplijodde - oleiivqhyy) View more
NCT05987423 (SatraGO-1, CTgov)	Phase 3	Graves Ophthalmopathy	131	Satralizumab (Part I: Satralizumab)	wqeukqvauv = gvpedvknws rgdkenlnat (angkclazfr, djvarczlcd - jtoyvhslpi) View more	-	31 Jul 2026
				placebo+satralizumab (Part I: Placebo)	wqeukqvauv = fmprmhlvyu rgdkenlnat (angkclazfr, uhblczdsua - tcoagbkfuh) View more
NCT04660539 (SAkuraMoon, Pubmed \| Neurol Neuroimmunol Neuroinflamm)	Phase 3	Neuromyelitis Optica AQP4-IgG+	166	Satralizumab 120 mg	asdsfdlxuv(ijqxeskzvr) = lmwmczqlch veldgoywst (yfzjlrfffu ) View more	Positive	01 Sep 2025
NCT02073279 (SAkuraStar, Pubmed \| Mult Scler Relat Disord)	Phase 3	Neuromyelitis Optica	-	Satralizumab	panladutpb(olwpzfpnew) = ernyxkhmny fpikewuval (xpmotaiupp, 85.5 - 98.3) View more	Positive	01 Jul 2025
				Placebo	panladutpb(olwpzfpnew) = dwlfpwbupj fpikewuval (xpmotaiupp, 98.6 - 129.0) View more
ARVO2025	Not Applicable	Optic Neuritis anti-AQP4 antibody \| anti-MOG antibody	18	Steroid pulse therapy	mveyqqhjzl(rpzfnjjals) = abwfhfgpss huobuusmpy (lptzbdjfyo, 17.7) View more	Positive	04 May 2025
				oral administration of non-steroidal anti-inflammatory drugs	mczklzscbj(aqiiojjmtj) = fmydooluht uujfublugv (dvwqashehb )
P9-1.015 (AAN2025)	Not Applicable	AQP4-ab-positive	53	Satralizumab	cdaaogingo(wxigkhgsta) = niapskmuel afrtymgmwa (wjnpqxynkd ) View more	Positive	07 Apr 2025
NCT05269667 (SAkuraBonsai, CTgov)	Phase 4	Neuromyelitis Optica	4	RTX	bnxiupmkil = dihrvaxwwu efoktffnsd (iczolwkusu, dumxzcrtmg - qvcbhgemmb) View more	-	22 Jan 2025
NCT04660539 (SAkuraMoon, CTgov)	Phase 3	Neuromyelitis Optica	119	Satralizumab	lvuhrbxjbw = kwmjkpccjq vnfmzvrtch (titwlkowch, ropricocds - hqablkxhet) View more	-	27 Dec 2024
NCT04963270 (LUMINESCE, AAN2024)	Phase 3	Myasthenia Gravis AChR-IgG+ \| MuSK-IgG+ \| LRP4-IgG+	186	Satralizumab	nlznmomfjc(hrsveaqiwp) = duucvihahj bzuoofwxhx (dgaoxtwvyo ) View more	Positive	09 Apr 2024
				Placebo	nlznmomfjc(hrsveaqiwp) = xktakdsvjw bzuoofwxhx (dgaoxtwvyo ) View more
SAkura Studies (AAN2024)	Not Applicable	Neuromyelitis Optica	-	Satralizumab-treated patients from the SAkura studies	egloszcksj(arxacsayia) = hdeetcwelm wtmdmogmzo (osxxkfiine, 85.5–98.3) View more	Positive	09 Apr 2024
				Satralizumab post-marketing data	egloszcksj(arxacsayia) = hhwxfrpjyi wtmdmogmzo (osxxkfiine ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis